ViiV Healthcare

Subsidiary of GlaxoSmithKline (GSK)

Assets

(10 total)
10Total Assets
5Approved
0Phase 3 / Filed
5Phase 1–2 / Early
1Diseases
Showing 10 of 10 assets
Target & Modality
Approved
HIV integraseSmall molecule
HIV
Approved
HIV integrase · HIV reverse transcriptaseSmall molecule
HIV
Dolutegravir(Tivicay / Triumeq / Dovato / Juluca (component))
Approved
HIV integraseSmall molecule
HIV
Fostemsavir(Rukobia)
Approved
HIV gp120Small molecule
HIV
Maraviroc(Selzentry / Celsentri)
Approved
CCR5 co-receptorSmall molecule
HIV
Phase 2
HIV capsidSmall molecule
HIV
Phase 2
HIV envelopeMonoclonal antibody
HIV
Phase 2
HIV capsidSmall molecule
HIV
Phase 2
HIV integraseSmall molecule
HIV
Phase 1
Undisclosed / early pipelineSmall molecule
HIV

Discontinued programmes (3)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
VH4524184Phase 2HIV Infections
Est. primary completion 2027-10-28 · NCT07202546 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
Cabotegravir (Apretude)Phase 3HIV Infections
Est. primary completion 2029-03-14 · NCT06134362 · CT.gov ↗
What to watch
August 2029 (1)
Est. primary completion 2029-08-13 · NCT07650916 · CT.gov ↗
What to watch
October 2029 (1)
Est. primary completion 2029-10-10 · NCT07275606 · CT.gov ↗
What to watch
2032 (2)
June 2032 (1)
Est. primary completion 2032-06-10 · NCT07816250 · CT.gov ↗
What to watch
September 2032 (1)
Est. primary completion 2032-09-14 · NCT07393659 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

September 2026Topline resultCabotegravir/rilpivirine (Cabenuva)CROWN meets its primary endpoint of superior viral suppression
ViiV Healthcare · Source ↗
5 August 2026WithdrawalFosamprenavirFDA withdraws approval of Lexiva, NDA 021548 and NDA 022116 (Federal Register 2026-13616)
US, FDA · Source ↗
25 February 2026Topline resultLotivibartEMBRACE Phase 2b 12-month interim: viral suppression 94% (IV) and 82% (SC) vs 88% standard of care
US · ViiV Healthcare · Source ↗

Financial reports

No financial reports recorded.